Uniform multidrug therapy for leprosy patients in Brazil (U-MDT/CT-BR): results of an open label, randomized and controlled clinical trial, among multibacillary patients

BACKGROUND: Leprosy control is based on early diagnosis and multidrug therapy. For treatment purposes, leprosy patients can be classified as paucibacillary (PB) or multibacillary (MB), according to the number of skin lesions. Studies regarding a uniform treatment regimen (U-MDT) for all leprosy patients have been encouraged by the WHO, rendering disease classification unnecessary. METHODOLOGY AND FINDINGS: An independent, randomized, controlled clinical trial conducted from 2007 to 2015 in Brazil, compared main outcomes (frequency of reactions, bacilloscopic index trend, disability progression and relapse rates) among MB patients treated with a uniform regimen/U-MDT (dapsone+rifampicin+clofazimine for six months) versus WHO regular-MDT/R-MDT (dapsone+rifampicin+clofazimine for 12 months). A total of 613 newly diagnosed, untreated MB patients with high bacterial load were included. There was no statistically significant difference in Kaplan-Meyer survival function regarding reaction or disability progression among patients in the U-MDT and R-MDT groups, with more than 25% disability progression in both groups. The full mixed effects model adjusted for the bacilloscopic index average trend in time showed no statistically significant difference for the regression coefficient in both groups and for interaction variables that included treatment group. During active follow up, four patients in U-MDT group relapsed representing a relapse rate of 2.6 per 1000 patients per year of active follow up (95% CI [0·81, 6·2] per 1000). During passive follow up three patients relapsed in U-MDT and one in R-MTD. As this period corresponds to passive follow up, sensitivity analysis estimated the relapse rate for the entire follow up period between 2·9- and 4·5 per 1000 people per year. CONCLUSION: Our results on the first randomized and controlled study on U-MDT together with the results from three previous studies performed in China, India and Bangladesh, support the hypothesis that UMDT is an acceptable option to be adopted in endemic countries to treat leprosy patients in the field worldwide.

Vigilância à saúde: endemias e epidemias: tuberculose e hanseníase

Este material contempla a disciplina optativa " Vigilância à saúde: endemias e epidemias: tuberculose e hanseníase" do Curso de Especialização Estratégia Saúde da Família (2014). Esta disciplina busca incentivar a equipe multidisciplinar das equipes de Saúde da Família a se organizar para o controle da tuberculose e hanseníase. O conteúdo está distribuído em quatro seções: Seção 1: Fatores determinantes e condicionantes das epidemias e endemias. Seção 2: Abordagem específica de doenças endêmicas e epidêmicas. Seção 3: Situação da tuberculose e da hanseníase. Seção 4: Casos clínicos: tuberculose e hanseníase

Endemias e epidemias: tuberculose e hanseníase

Este módulo integra a disciplina optativa " Vigilância à saúde: endemias e epidemias: tuberculose e hanseníase" do Curso de Especialização Estratégia Saúde da Família (2014). Esta disciplina busca incentivar a equipe multidisciplinar das equipes de Saúde da Família a se organizar para o controle da tuberculose e hanseníase. O conteúdo está distribuído em quatro seções: Seção 1: Fatores determinantes e condicionantes das epidemias e endemias. Seção 2: Abordagem específica de doenças endêmicas e epidêmicas. Seção 3: Situação da tuberculose e da hanseníase. Seção 4: Casos clínicos: tuberculose e hanseníase

The influence of ML Flow test in leprosy classification.

This is a descriptive, exploratory study correlating ML Flow, bacilloscopy and classification of paucibacillary (PB) and multibacillary (MB), involving 1,041 new leprosy cases in 13 municipalities of Minas Gerais State, from October 2002 to March 2004. Agreement between ML Flow and the classification of the number of skin lesions and bacilloscopy was moderate (K:0.51 and K:0.48, respectively); and substantial for final classification (K:0.77). From January 2000 to March 2004, the proportion of new MB cases in Minas Gerais decreased from 78.1 to 65.8%. The reduction in the percentage of MB cases was higher in health centers that participated in the ML Flow study (73.1% to 53.3%). The difference between PB and MB in the participating and non-participating health centers from January to March 2004 was statistically significant. Implementation of the ML Flow test influenced the classification of patients, suggesting a direct and beneficial impact on patient treatment and the control of the leprosy endemic in Minas Gerais, Brazil.

Risk factors for ML Flow seropositivity in leprosy patients.

The early diagnosis of leprosy, its correct classification and the risk factors related to seropositivity have become important for patient treatment and disease control, especially where the responsibility for treatment has been transferred to basic health care centers. This descriptive, exploratory study using logistic regression was undertaken to evaluate the association between the variables of sex, age, mode of detection, number of skin lesions and affected nerves, disability grade and bacilloscopy with the results of the ML Flow serological test in 1,072 new leprosy cases in 13 municipalities in Minas Gerais State. Seropositivity (50.7%) was statistically associated with patients 15 years-old or over (OR:2.6) and those with more than five skin lesions (OR:7.5), more than one affected nerve (OR:2.4) and a positive bacilloscopic index (OR:5.5 for 0or=2), thus contributing to the appropriate classification and treatment of patients.

Seroprevalence of ML Flow test in leprosy contacts from State of Minas Gerais, Brazil.

Leprosy is a public health problem in Brazil. Epidemiological control actions are based on the diagnosis and treatment of leprosy patients and household contact surveillance. Serological tests for leprosy could identify from among the contacts those at greater risk of developing leprosy in the future. ML Flow was administered to 2,840 household contacts of new leprosy cases diagnosed from October 2002 to March 2004, in State of Minas Gerais. ML Flow was positive in 20.5% of leprosy contacts, with high seropositivity among males (22.4%), individuals aged over 15 years-old (21.7%) and individuals in contact with multibacillary cases (23.9%). The chances of a household contact presenting a seropositive test was related to household contact with a multibacillary index case (OR=1.75), age over 15 years-old (OR=1.38) and male gender (OR=1.25). Follow-up of these contacts is necessary to evaluate the real role of seropositivity in the development of leprosy disease.

A influência do teste sorológico ML Flow na classificação da hanseníase / The influence of ML Flow test in leprosy classification

Estudo descritivo e exploratório correlacionando o ML Flow, a baciloscopia e a classificação em paucibacilar (PB) e multibacilar (MB), envolveu 1.041 casos novos com hanseníase em 13 municípios de Minas Gerais, de outubro de 2002 a março de 2004. A concordância entre o ML Flow e a classificação pelo número de lesões cutâneas e a baciloscopia foi moderada (Kappa:0,51 e 0,48, respectivamente) e, substancial (Kappa:0,77) com a classificação final. De janeiro de 2000 a março de 2004, a proporção de casos novos MB no Estado, passou de 78,1 para 65,8%. A queda no percentual de MB foi maior nos serviços participantes da pesquisa ML Flow (73,1 para 53,3%). A diferença de PB e MB nos serviços participantes e não participantes, de janeiro a março de 2004, foi estatisticamente significativa, indicando implicação direta e benéfica no tratamento e no controle da endemia em Minas Gerais.

This is a descriptive, exploratory study correlating ML Flow, bacilloscopy and classification of paucibacillary (PB) and multibacillary (MB), involving 1,041 new leprosy cases in 13 municipalities of Minas Gerais State, from October 2002 to March 2004. Agreement between ML Flow and the classification of the number of skin lesions and bacilloscopy was moderate (K:0.51 and K:0.48, respectively); and substantial for final classification (K:0.77). From January 2000 to March 2004, the proportion of new MB cases in Minas Gerais decreased from 78.1 to 65.8%. The reduction in the percentage of MB cases was higher in health centers that participated in the ML Flow study (73.1% to 53.3%). The difference between PB and MB in the participating and non-participating health centers from January to March 2004 was statistically significant. Implementation of the ML Flow test influenced the classification of patients, suggesting a direct and beneficial impact on patient treatment and the control of the leprosy endemic in Minas Gerais, Brazil.

Fatores de risco para a soropositividade do ML Flow em pacientes com hanseníase / Risk factors for ML Flow seropositivity in leprosy patients

O diagnóstico precoce da hanseníase, a correta classificação e o estudo dos fatores de risco relacionados à soropositividade, tornam-se importantes para o tratamento do doente e controle da endemia, especialmente, quando a responsabilidade pelo atendimento desses pacientes está sendo absorvida pelos serviços de atenção básica. Estudo descritivo e exploratório utilizando regressão logística avaliou a associação das variáveis: sexo, idade, modo de detecção, número de lesões cutâneas e de nervos acometidos, grau de incapacidade, baciloscopia, com o resultado do teste sorológico ML Flow, em 1.072 casos novos com hanseníase em 13 municípios de Minas Gerais. A soropositividade (50,7%) estava estatisticamente associada aos pacientes com 15 anos ou mais de idade (OR:2,6), mais de cinco lesões cutâneas (OR:7,5), mais de um nervo acometido (OR:2,4) e com baciloscopia positiva (OR:5,5 para IB<2 e OR:191,2 para IB>2), colaborando, assim, com a classificação e o tratamento adequados dos doentes.

The early diagnosis of leprosy, its correct classification and the risk factors related to seropositivity have become important for patient treatment and disease control, especially where the responsibility for treatment has been transferred to basic health care centers. This descriptive, exploratory study using logistic regression was undertaken to evaluate the association between the variables of sex, age, mode of detection, number of skin lesions and affected nerves, disability grade and bacilloscopy with the results of the ML Flow serological test in 1,072 new leprosy cases in 13 municipalities in Minas Gerais State. Seropositivity (50.7%) was statistically associated with patients 15 years-old or over (OR:2.6) and those with more than five skin lesions (OR:7.5), more than one affected nerve (OR:2.4) and a positive bacilloscopic index (OR:5.5 for 02), thus contributing to the appropriate classification and treatment of patients.

Soroprevalência do teste ML Flow em contatos de hanseníase de Minas Gerais / Seroprevalence of ML Flow test in leprosy contacts from State of Minas Gerais, Brazil

A hanseníase é um problema de saúde pública no Brasil. As ações de controle estão baseadas no diagnóstico e tratamento dos indivíduos doentes e na vigilância de seus contatos. Os testes sorológicos permitem identificar, entre os contatos, aqueles com maior risco de desenvolver hanseníase. O ML Flow foi utilizado em 2.840 contatos intradomiciliares de casos novos de hanseníase, diagnosticados entre outubro de 2002 e março de 2004, em Minas Gerais. O ML Flow foi positivo em 20,5% dos contatos de hanseníase, sendo maior nos contatos do sexo masculino (22,4%), nos maiores de 15 anos (21,7%), nos contatos de doentes multibacilares (23,9%). A chance de um contato ser soropositivo foi maior se convivia com caso multibacilar (OR=1,75), idade superior a 15 anos (OR=1,38) e sexo masculino (OR=1,25). O acompanhamento desses contatos permitirá, no futuro, avaliar o risco que a soropositividade representa no desenvolvimento de hanseníase.

Leprosy is a public health problem in Brazil. Epidemiological control actions are based on the diagnosis and treatment of leprosy patients and household contact surveillance. Serological tests for leprosy could identify from among the contacts those at greater risk of developing leprosy in the future. ML Flow was administered to 2,840 household contacts of new leprosy cases diagnosed from October 2002 to March 2004, in State of Minas Gerais. ML Flow was positive in 20.5% of leprosy contacts, with high seropositivity among males (22.4%), individuals aged over 15 years-old (21.7%) and individuals in contact with multibacillary cases (23.9%). The chances of a household contact presenting a seropositive test was related to household contact with a multibacillary index case (OR=1.75), age over 15 years-old (OR=1.38) and male gender (OR=1.25). Follow-up of these contacts is necessary to evaluate the real role of seropositivity in the development of leprosy disease.

Talidomida: indicaçöes e legislaçäo vigente / Thalidomide: indications and actual legislation

A talidomida, droga que tem ampla aplicaçäo clínica e potentes efeitos antiinflamatórios, qualifica-se como primeira escolha para tratamento de várias doenças. Seu efeito teratogênico, entretanto, limita seu uso clínico. Baseando-se neses conhecimentos, após estudo detalhado de cada um de seus efeitos, e avaliando-se cuidadosamente o risco/benefício de seu emprego, pretende-se indicar a talidomida para algumas situaçöes clínicas já bem estabelecidas. Säo elas: eritema nodoso hansênico, lúpus eritematoso discóide, estomatite aftosa recorrente, doença enxerto-verus-hospedeiro em sua fase crônica, úlceras dolorosas de mucosas em pacientes com HIV/Aids, prurigo nodular, síndrome de Behçet e prurigo actínico. A essas somam-se outras, em que seu uso só deve se indicado se outras drogas resultarem ineficazes. Complementando a avaliaçäo, foram consideradas as situaçöes nas quais a talidomida poderia ser eficaz, necessitando de estudo prévio das características da doença e do paciente para que se efetive sua utilizaçäo. O uso da talidomida deve sempre obedecer às portarias do Ministério da Saúde que regulamentam sua fabricaçäo, indicaçöes e dispensäo. Os principais pontos dessa legislaçäo seräo destacados, em especial a proibiçäo para uso em mulheres em idade fértil.